Phase I/II Pilot Study of Intravesical Apaziquone (EO9) for Superficial Bladder Cancer

Journal of Urology

Volumn 176, Issue 4, 2006, Pages 1344-1348

  Puri, Rajiv ^a   Palit, Victor ^a   Loadman, Paul M ^f   Flannigan, Michael ^a   Shah, Tariq ^a   Choudry, Guzanfar A ^a   Basu, Saurajyoti ^a   Double, John A ^b   Lenaz, Gino ^c   Chawla, Shanta ^c   Beer, Mario ^c   Van Kalken, Coen ^d   de Boer, Richard ^d   Beijnen, Jos H ^e   Twelves, Christopher J ^b   Phillips, Roger M ^b  

^a BRADFORD ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF BRADFORD   (United Kingdom)

^c Spectrum Pharmaceuticals   (United States)

^d NDDO Oncology   (Netherlands)

^e SLOTERVAART HOSPITAL   (Netherlands)

^f NONE

Author keywords

bladder; bladder neoplasms; carcinoma; EO9; transitional cell

Indexed keywords

APAZIQUONE; ENZYME; EOQUIN; GLUCOSE TRANSPORTER 1; QUINONE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE:QUINONE OXIDOREDUCTASE 1; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG URINE LEVEL; DYSURIA; FEMALE; HEMATURIA; HUMAN; MALE; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUPERFICIAL CANCER; TRANSITIONAL CELL CARCINOMA;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AZIRIDINES; CARCINOMA, TRANSITIONAL CELL; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDOLEQUINONES; MALE; MIDDLE AGED; PILOT PROJECTS; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 33748094636     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2006.06.047     Document Type: Article

References (18)

1. Workman P. Enzyme directed bioreductive drug development revisited. a commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolising enzymes, particularly DT-diaphorase. Oncol Res 6 (1994) 461
2. Robertson N., Haigh A., Adams G.E., and Stratford I.J. Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro. DT-diaphorase activity and hypoxia. Eur J Cancer 30A (1994) 1013
3. Fitzsimmons S.A., Workman P., Grever M., Paull K., Camalier R., and Lewis A.D. Reductase enzyme expression across the National Cancer Institute tumour cell line panel. correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 88 (1996) 259
4. Plumb J.A., Gerritsen M., and Workman P. DT-diaphorase protects cells from the hypoxic cytotoxicity of indolequinone EO9. Br J Cancer 70 (1994) 1136
5. Hendriks H.R., Pizao P.E., Berger D.P., Kooistra K.L., Bibby M.C., Boven E., et al. EO9. a novel bioreductive alkylating indolequinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. Eur J Cancer 29A (1993) 897
6. Schellens J.H., Planting A.S., van Acker B.A., Loos W.J., de Boer-Dennert M., van der Berg M.E., et al. Phase I and pharmacological study of the novel indolequinone bioreductive alkylating cytotoxic drug EO9. J Natl Cancer Inst 86 (1994) 906
7. Pavlidis N., Hanauske A.R., Gamucci T., Smyth J., Lehnert M., te Velde A., et al. A randomized phase II study with two schedules of the novel indolequinone EO9 in non-small-cell lung cancer. a study of the EORTC Early Clinical Studies Group (ECSG). Ann Oncol 7 (1996) 529
8. Dirix L.Y., Tonnesen F., Cassidy J., Epelbaum R., ten Bokkel-Huinink W.W., Pavlidis N., et al. EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group. Eur J Cancer 32A (1996) 2019
9. Phillips R.M., Loadman P.M., and Cronin B.P. Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. Br J Cancer 77 (1998) 2112
10. Loadman P.M., Bibby M.C., and Phillips R.M. Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9. Br J Pharmacol 137 (2002) 701
11. Choudry G.A., Hamilton Stewart P.A., Double J.A., Krul M.R., Naylor B., Flannigan M., et al. A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9. Br J Cancer 85 (2001) 1137
12. Hoskin P.J., Sibtain A., Daley F.M., and Wilson G.D. GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer. relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer 89 (2003) 1290
13. Van der Meijden A.P. The use of the marker tumour concept in Ta, T1 bladder cancer. is it justified?. Urol Oncol 7 (2002) 31
14. Phillips R.M., Hulbert P.B., Bibby M.C., Sleigh N.R., and Double J.A. In vitro activity of the novel indolequinone EO9 and the influence of pH on cytotoxicity. Br J Cancer 65 (1992) 359
15. Basu S., Brown J.E., Flannigan G.M., Gill J.H., Loadman P.M., Martin S.W., et al. Immunohistochemical analysis of NQO1 and cytochrome P450 reductase in human superficial bladder tumours. relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy. Int J Cancer 109 (2004) 703
16. Airley R.E., Loncaster J., Raleigh J.A., Harris A.L., Davidson S.E., Hunter R.D., et al. Glut-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix. relationship to pimonidazole binding. Int J Cancer 104 (2003) 85
17. Saunders M., Jaffar M., Patterson A.V., Nolan J., Naylor M.A., Phillips R.M., et al. The relative importance of NADPH:cytochrome C (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions. Biochem Pharmacol 59 (2000) 993
18. Samuni A.M., DeGraff W., Krishna M.C., and Mitchell J.B. Nitroxides as antioxidants. Tempol protects against EO9 cytotoxicity. Mol Cell Biochem 234-235 (2002) 327